Research Article
Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement
Table 3
All treatment-related toxicities (possibly, probably, or definitely related)a.
| | Adverse event | Treatment arm | | Pazopanib 600 mg once daily for a 28-day cycle (n = 12) | | Grade 1 | Grade 2 | Grade 3 |
| | Hypertension | 1 (8%) | 1 (8%) | 1 (8%) | | Ejection fraction decreased | — | 1 (8%) | 1 (8%) | | Elevated bilirubin | — | — | 1 (8%) | | Transaminases | — | — | 1 (8%) | | Fatigue | 1 (8%) | 2 (17%) | — | | Pain | 1 (8%) | 2 (17%) | — | | Diarrhea | 7 (58%) | 1 (8%) | — | | Nausea/vomiting | 5 (42%) | 1 (8%) | — | | Hypothyroidism | 3 (25%) | 1 (8%) | — | | Neutropenia | 2 (17%) | 1 (8%) | — | | Anemia | — | 1 (8%) | — | | Body aches | — | 1 (8%) | — | | Palmar-plantar erythrodysesthesia | — | 1 (8%) | — | | Right mandibular infection | — | 1 (8%) | — | | Tachycardia | — | 1 (8%) | — | | White blood cell count decreased | — | 1 (8%) | — | | White blood cell count increased | — | 1 (8%) | — | | Anorexia | 4 (33%) | — | — | | Abdominal pain | 3 (25%) | — | — | | Platelet count decreased | 3 (25%) | — | — | | Dizziness | 2 (17%) | — | — | | Weight loss | 2 (17%) | — | — |
|
|
aAll treatment-related (possibly, probably, or definite) except for grade 1 AEs that occurred in only one patient.
|
